Infectious Disease Advisor news story
Switching to long-acting antiretroviral therapy (ART) with cabotegravir (CAB) plus rilpivirine (RPV) does not appear to increase risk for hepatitis B virus (HBV) reactivation or incident infection in patients with HIV. However, pre-switch risk assessment and continued monitoring are advised in the setting of chronic HBV. These study findings were published in Clinical Infectious Diseases.
CAB/RPV does not have activity against HBV, raising concerns about viral reactivation or new infection in individuals with prior exposure or incomplete immunity. Evidence addressing this risk in routine clinical practice has remained limited.
Researchers in Spain conducted a prospective cohort study of adults with HIV who initiated long-acting CAB/RPV at Hospital Clínic Barcelona between February 2023 and February 2025. They evaluated baseline HBV serologic profiles and assessed the incidence of HBV reactivation and incident infection following the switch to long-acting ART.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
-
European Medical Journal: The rising burden of frailty in people with HIV
-
[Press release] EMA: First immunotherapy-based treatment recommended for advanced anal cancer
-
[Press release] nChroma Bio announces first patient dosed in Phase 1/2 clinical trial of epigenetic silencer CRMA-1001 for chronic hepatitis B
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.